Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"
Incyte Corporation -0.07%
Novartis AG Sponsored ADR -0.11%
Incyte Corporation INCY | 69.86 | -0.07% |
Novartis AG Sponsored ADR NVS | 98.24 | -0.11% |
https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html